The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.
 
Daniel Morgensztern
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Medarex
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Bristol-Myers Squibb; G1 Therapeutics; Lilly Medical; Mirati Therapeutics
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxter (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Heat Biologics (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Y-mAbs Therapeutics (Inst)
 
Neal E. Ready
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Celgene; G1 Therapeutics; Jazz Pharmaceuticals; Merck; Merck Serono; Novartis; Pfizer; Regeneron; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Jazz Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Memgen (Inst); Merck
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Axiom (Inst); Novartis (Inst); Oncorus (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); SeaGen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); VBL Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck; Tempus
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Coordination Pharmaceuticals (Inst); Gilead Sciences (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Pionyr (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst)
 
Noura J. Choudhury
Consulting or Advisory Role - G1 Therapeutics; Sanofi
Research Funding - Abbvie (Inst); Amgen (Inst); Harpoon therapeutics (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Wolters Kluwer (Pocket Oncology).
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech/Roche; GlaxoSmithKline; Intellisphere; InThought; Iovance Biotherapeutics; Janssen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Merck KGaA; Mirati Therapeutics; MSD Oncology; NCCN/AstraZeneca; Novartis; OncLive/MJH Life Sciences; Pfizer; PPD; Regeneron; Roche; Sanofi
 
Eric S. Schaefer
Employment - Highlands Oncology
Leadership - Quality Community Cancer Alliance
Honoraria - Quality Cancer Care Alliance
Consulting or Advisory Role - Amgen; Mirati Therapeutics
 
Susanne M. Arnold
Consulting or Advisory Role - Penn State Cancer Institute
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Ellipses Pharma (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); LabCorp (Inst); Merck Sharp & Dohme (Inst); National Cancer Institute (Inst); Nektar (Inst); Ohio State University (Inst); Regeneron (Inst); Syneos Health (Inst)
 
Sonam Puri
Honoraria - Aptitude Health (Inst); IntegrityCE
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst); Jazz Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Zofia Piotrowska
Consulting or Advisory Role - AstraZeneca; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo Europe GmbH; Janssen; Lilly; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); ARIAD/Takeda (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline/Tesaro (Inst); GlaxoSmithKline/Tesaro (Inst); Janssen Oncology (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune
 
Aparna Madhukeshwar Hegde
No Relationships to Disclose
 
Anne C. Chiang
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daichi; Flatiron Health; Genentech; Genentech; Genentech/Roche; Jazz Pharmaceuticals; regeneron; Sanofi/Regeneron
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Millennium; OncoMed; Onyx; Stem CentRx
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
Wade Thomas Iams
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Pfizer; Chardan Consulting; Curio Science; Defined Health; G1 Therapeutics; Janssen; Jazz Pharmaceuticals; Mirati Therapeutics; Novocure; Outcomes Insights; Sanofi; Takeda
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bright Peak Therapeutics (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Eleven Biotherapeutics (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Kirilys Therapeutics (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Link Immunotherapeutics (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nerviano Medical Sciences (Inst); Novo Nordisk (Inst); Nurix (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Pyxis (Inst); Qualigen Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sunshine Guojian (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); VRise Therapeutics (Inst); Zentalis (Inst); ZielBio (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Kaname Nosaki
Honoraria - AstraZeneca; Chugai Pharma; Janssen; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Daiichi Sankyo/UCB Japan
Research Funding - Abbvie (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD K.K (Inst); Takeda (Inst)
 
Jiuhong Zha
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Rui Li
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Pooja Hingorani
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Edwin E. Jeng
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Muhammad Furqan
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; BeiGene; Jazz Pharmaceuticals; Mirati Therapeutics; Novartis; Omega Therapeutics
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Biothera (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jacobus Pharmaceutical Company (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst)